Olokizumab

Olokizumab (CDP 6038) is a humanized monoclonal antibody that targets interleukin-6 (IL-6) . Olokizumab inhibits IL-6-induced STAT-3 phosphorylation. Olokizumab is used in the study of arthritis[1][2][3].

Product Specifications

CAS Number

[1007223-17-7]

Product Name Alternative

CDP 6038; OKZ

UNSPSC

12352203

Target

Interleukin Related; STAT

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Endocrinology; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/olokizumab.html

Purity

99.54

Solubility

10 mM in DMSO

Smiles

[Olokizumab]

Molecular Weight

(145.94 kDa)

References & Citations

[1]Kretsos K, et, al. Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab. CPT Pharmacometrics Syst Pharmacol. 2014 Jun 18;3 (6) :e119.|[2]Shaw S, et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6 (3) :774-82.|[3]Tavakolpour S. Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases. Receptors & Clinical Investigation, 2016, 3.